Loading clinical trials...
Loading clinical trials...
A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
Conditions
Interventions
AZD1775
Locations
3
United States
Research Site
Scottsdale, Arizona, United States
Research Site
Denver, Colorado, United States
Research Site
Nashville, Tennessee, United States
Start Date
December 1, 2015
Primary Completion Date
April 26, 2018
Completion Date
April 26, 2018
Last Updated
July 3, 2023
NCT03050268
NCT06257264
NCT06964009
NCT00539162
NCT06915025
NCT06710548
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions